Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alembic Pharmaceuticals Limited (APLLTD.NS)
INR850.05
+28.90 (+3.52%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Alembic Road 390003
Vadodara, IN
Vadodara, IN
CEO
Chirayu Ramanbhai Amin
Website
alembicpharmaceuticals.com
IPO
2011-09-20
ISIN INE901L01018
Also trades on
Bombay Stock Exchange · APLLTD.BO (INR)
National Stock Exchange of India · APLLTD.NS (INR)
Description
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR850.05
+28.90 (+3.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
160.5K
Beta
0.38
Float Shares
57.87M
Free Float %
29.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.61% | +0.75% | -0.49% | +0.50% | -17.70% | -7.71% | -24.08% | +37.57% | -17.25% | +36.08% | +1,612.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
850.05
DCF (Unlevered)
391.35
-54.0%
DCF (Levered)
193.96
-77.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
64% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.39
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.1% ★ Q1'26: +4.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.7% Q1'26: +29.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.8% Q1'26: +9.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.9% Q1'26: +7.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+11.2% ★ Q1'26: +8.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.28× Q1'26: 1.57× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 7 EPS Ana. |
Mar 2027 11 Rev. Ana. 11 EPS Ana. |
Mar 2028 11 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.66B
est: 14.43B (+1.6%)
|
15.20B
est: 15.43B (-1.4%)
|
20.58B
est: 18.86B (+9.1%)
|
20.58B
est: 20.87B (-1.4%)
|
31.23B
est: 32.67B (-4.4%)
|
31.05B
est: 31.89B (-2.6%)
|
31.30B
est: 31.26B (+0.1%)
|
39.35B
est: 39.42B (-0.2%)
|
46.06B
est: 45.94B (+0.2%)
|
53.93B
est: 54.27B (-0.6%)
|
53.06B
est: 51.76B (+2.5%)
|
56.53B
est: 56.29B (+0.4%)
|
62.29B
est: 63.04B (-1.2%)
|
66.72B
est: 65.26B (+2.2%)
|
74.11B
73.71B – 74.80B
+13.6% YoY
|
82.32B
80.99B – 83.67B
+11.1% YoY
|
90.55B
88.94B – 93.03B
+10.0% YoY
|
| EBITDA |
2.32B
est: 2.46B (-5.6%)
|
2.49B
est: 1.74B (+43.2%)
|
3.99B
est: 2.86B (+39.8%)
|
3.99B
est: 3.85B (+3.7%)
|
10.03B
est: 6.37B (+57.4%)
|
6.21B
est: 9.86B (-36.9%)
|
6.15B
est: 5.87B (+4.9%)
|
8.56B
est: 8.36B (+2.3%)
|
12.55B
est: 9.92B (+26.5%)
|
14.66B
est: 13.70B (+7.0%)
|
8.59B
est: 15.12B (-43.2%)
|
6.96B
est: 16.11B (-56.8%)
|
9.14B
est: 10.74B (-14.9%)
|
9.89B
est: 19.95B (-50.4%)
|
12.63B
12.56B – 12.74B
-36.7% YoY
|
14.02B
13.80B – 14.25B
+11.1% YoY
|
15.43B
15.15B – 15.85B
+10.0% YoY
|
| EBIT |
1.99B
est: 1.86B (+6.8%)
|
2.14B
est: 2.06B (+4.1%)
|
3.55B
est: 2.62B (+35.6%)
|
3.55B
est: 3.58B (-0.8%)
|
9.31B
est: 5.53B (+68.5%)
|
5.38B
est: 9.13B (-41.0%)
|
5.10B
est: 5.27B (-3.3%)
|
7.41B
est: 6.42B (+15.5%)
|
11.11B
est: 8.53B (+30.3%)
|
12.97B
est: 11.88B (+9.2%)
|
5.87B
est: 13.11B (-55.2%)
|
4.38B
est: 13.97B (-68.7%)
|
6.61B
est: 8.12B (-18.6%)
|
7.30B
est: 8.39B (-13.0%)
|
9.55B
9.50B – 9.64B
+13.8% YoY
|
10.60B
10.43B – 10.78B
+11.1% YoY
|
11.66B
11.46B – 11.98B
+10.0% YoY
|
| Net Income |
1.30B
est: 1.23B (+5.7%)
|
1.65B
est: 1.39B (+18.9%)
|
2.83B
est: 2.02B (+40.0%)
|
2.83B
est: 2.66B (+6.5%)
|
7.20B
est: 4.43B (+62.7%)
|
4.03B
est: 7.05B (-42.8%)
|
4.13B
est: 3.95B (+4.4%)
|
5.84B
est: 5.20B (+12.5%)
|
8.29B
est: 6.73B (+23.2%)
|
11.47B
est: 9.71B (+18.1%)
|
5.21B
est: 10.72B (-51.4%)
|
3.42B
est: 5.28B (-35.3%)
|
6.16B
est: 6.30B (-2.2%)
|
5.83B
est: 5.73B (+1.9%)
|
6.66B
6.65B – 7.16B
+16.3% YoY
|
8.30B
7.00B – 8.85B
+24.5% YoY
|
9.93B
8.21B – 10.77B
+19.7% YoY
|
| SGA |
1.20B
est: 3.13B (-61.6%)
|
4.32B
est: 4.31B (+0.1%)
|
3.16B
est: 5.56B (-43.1%)
|
3.16B
est: 4.71B (-32.9%)
|
4.87B
est: 11.51B (-57.7%)
|
5.74B
est: 8.40B (-31.7%)
|
6.37B
est: 10.27B (-38.0%)
|
7.77B
est: 13.32B (-41.6%)
|
9.09B
est: 16.21B (-43.9%)
|
10.51B
est: 16.78B (-37.3%)
|
11.38B
est: 18.52B (-38.5%)
|
11.75B
est: 19.73B (-40.4%)
|
14.49B
est: 13.68B (+5.9%)
|
15.68B
est: 24.44B (-35.9%)
|
16.08B
16.00B – 16.23B
-34.2% YoY
|
17.86B
17.58B – 18.16B
+11.1% YoY
|
19.65B
19.30B – 20.19B
+10.0% YoY
|
| EPS |
6.90
est: 6.26 (+10.2%)
|
8.77
est: 7.83 (+12.0%)
|
15.01
est: 12.41 (+20.9%)
|
15.01
est: 15.22 (-1.4%)
|
38.19
est: 38.34 (-0.4%)
|
21.39
est: 22.44 (-4.7%)
|
21.89
est: 23.67 (-7.5%)
|
31.00
est: 29.72 (+4.3%)
|
43.97
est: 44.12 (-0.3%)
|
59.18
est: 58.31 (+1.5%)
|
26.50
est: 35.75 (-25.9%)
|
17.40
est: 20.92 (-16.8%)
|
31.33
est: 32.03 (-2.2%)
|
29.68
est: 29.04 (+2.2%)
|
35.10
33.84 – 36.43
+20.9% YoY
|
40.87
35.59 – 45.02
+16.4% YoY
|
48.94
41.77 – 54.79
+19.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.05B
OE per share TTM
15.50
Owner's Yield
1.98%
Maintenance CapEx ratio
55.28%
Maint CapEx / Avg PPE
57.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.61M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.83M | 0.06% |
| 3 | Vanguard ESG International Stock ETF VSGX | 0.00% | 75.3K | 0.10% |
| 4 | Vanguard Total International Stock ETF VXUS | 0.00% | 6.35M | 0.05% |
| 5 | Vanguard Total World Stock ETF VT | 0.00% | 358.7K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
538.4K
Shares Outstanding
196.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pranav Chirayu Amin | MD & Executive Director | 191M | male |
| Shaunak Chirayu Amin | MD & Executive Director | 191M | male |
| Chirayu Ramanbha Amin | Executive Chairman | 141M | male |
| Raj Kumar Shreeram Baheti | Executive Director | 83M | male |
| Ajay Kumar Desai | Senior Vice President of Finance | 9M | male |
| Sachin Ghosalkar | Senior Vice President of SCM & Operations | — | — |
| Udit C. Amin | Chief Business Development Officer | — | male |
| Amresh Choudhary | Head-Legal & Taxation | — | male |
| G. Krishnan | Chief Financial Officer | — | male |
| J. Venkat Raman S. | Chief Scientific Officer | — | — |
| Manisha Saraf | Company Secretary & Compliance Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APLLTD.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
